- Research works
- 58 ▼ 63% vs 2013–17
- Citations
- 593 10.3 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 14% world 28%
Not ranked overall: Omnicare Pharma (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 9.8×. Every wedge is a field page.
Which keywords describe research at Omnicare Pharma (Germany)?
By fractional works in all years, weighted toward what it does more of than the world: Quality of Life, Cardiovascular Disease, Epidemiology, Heart Failure, Inflammation, Aging, Clinical Trials and Elderly.
- Type 2 Diabetes
- Drug Development
- Wavelet Transform
- Prevention Strategies
- Patient Safety
- Probiotics
- Immune System
- Gastrointestinal Disorders
- Elderly Patients
- Insulin Therapy
- Healthcare-Associated Infections
- Cost-effectiveness Analysis
- Primary Care
- Quality of Care
- Glycemic Control
- Elderly
- Diabetes
- Aging
- Inflammation
- Quality of Life
- Epidemiology
- Cardiovascular Disease
- Heart Failure
- Clinical Trials
- Diagnosis
- Chronic Kidney Disease
- Nursing Home
- Clinical Practice Guidelines
- Clinical Guidelines
- Health Utility Measures
- Inappropriate Medication Use
- Polypharmacy
- Global Burden
- Health Information Management
- Neuropathology
- Cancer Cachexia
- Sarcopenia
- Urinary Incontinence
- Cardiovascular Outcomes
- Mortality Risk
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology6▲ 2.7×15 topics
- Quality of Life5▲ 6.1×10 topics
- Cardiovascular Disease4▲ 6.8×11 topics
- Inflammation4▲ 3.2×10 topics
- Heart Failure3▲ 12×7 topics
- Aging3▲ 9.2×4 topics
- Clinical Trials3▲ 7.3×8 topics
- Diabetes2▲ 8.3×6 topics
- Diagnosis2▲ 4.2×5 topics
- Elderly2▲ 18×4 topics
- Chronic Kidney Disease2▲ 17×7 topics
- Glycemic Control2▲ 26×4 topics
- Nursing Home2▲ 94×1 topic
- Quality of Care2▲ 46×1 topic
- Clinical Practice Guidelines2▲ 6.0×4 topics
- Primary Care2▲ 7.3×4 topics
- Clinical Guidelines2▲ 9.3×3 topics
- Cost-effectiveness Analysis2▲ 38×1 topic
- Health Utility Measures2▲ 38×1 topic
- Healthcare-Associated Infections2▲ 24×4 topics
- Inappropriate Medication Use2▲ 71×1 topic
- Insulin Therapy2▲ 25×3 topics
- Polypharmacy2▲ 71×1 topic
- Elderly Patients2▲ 20×4 topics
- Global Burden1▲ 4.5×3 topics
- Gastrointestinal Disorders1▲ 38×2 topics
- Health Information Management1▲ 135×2 topics
- Immune System1▲ 7.1×2 topics
- Neuropathology1▲ 27×2 topics
- Probiotics1▲ 9.3×2 topics
- Cancer Cachexia1▲ 36×1 topic
- Patient Safety1▲ 17×2 topics
- Sarcopenia1▲ 36×1 topic
- Prevention Strategies1▲ 20×2 topics
- Urinary Incontinence1▲ 21×2 topics
- Wavelet Transform1▲ 9.6×3 topics
- Cardiovascular Outcomes1▲ 42×1 topic
- Drug Development1▲ 13×2 topics
- Mortality Risk1▲ 8.7×2 topics
- Type 2 Diabetes1▲ 9.5×1 topic
Which research topics does Omnicare Pharma (Germany) publish most on?
By volume in 2022–2025: Cannabis and Cannabinoid Research, Biosimilars and Bioanalytical Methods, Biomedical Ethics and Regulation and CAR-T cell therapy research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cannabis and Cannabinoid Research Pharmacology 0 works
- 2 Biosimilars and Bioanalytical Methods Immunology 0 works
- 3 Biomedical Ethics and Regulation Physiology 0 works
- 4 CAR-T cell therapy research Oncology 0 works
- 5 Heart Failure Treatment and Management Cardiology and Cardiovascular Medicine 0 works
- 6 Sleep and Wakefulness Research Cognitive Neuroscience 0 works
- 7 Sleep and related disorders Experimental and Cognitive Psychology 0 works
- 8 Pulmonary Hypertension Research and Treatments Pulmonary and Respiratory Medicine 0 works
- 9 Cardiovascular and exercise physiology Complementary and alternative medicine 0 works
- 10 Mobile Health and mHealth Applications General Health Professions 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Omnicare Pharma (Germany)'s research output changed?
Output in 2018–2022 was 63% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.